Human Pathology
Volume 40, Issue 9 , Pages 1244-1251 , September 2009

Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays

  • Hongwei Cheng, MD, PhD

      Affiliations

    • Vancouver Coastal Health Research Institute and University of British Columbia, Canada V5Z1M9
    • ,
  • Jim Dodge

      Affiliations

    • Vancouver Coastal Health Research Institute and University of British Columbia, Canada V5Z1M9
    • ,
  • Erika Mehl, BMLS

      Affiliations

    • Vancouver Coastal Health Research Institute and University of British Columbia, Canada V5Z1M9
    • ,
  • Shuzhen Liu, BSc, MSc

      Affiliations

    • Vancouver Coastal Health Research Institute and University of British Columbia, Canada V5Z1M9
    • ,
  • Neal Poulin, PhD

      Affiliations

    • Vancouver Coastal Health Research Institute and University of British Columbia, Canada V5Z1M9
    • ,
  • Matt van de Rijn, MD, PhD

      Affiliations

    • Department of Pathology, Stanford University, CA 94305, USA
    • ,
  • Torsten O. Nielsen, MD, PhD

      Affiliations

    • Vancouver Coastal Health Research Institute and University of British Columbia, Canada V5Z1M9
    • Corresponding Author InformationCorresponding author. Anatomical Pathology JP1401, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada V5Z1M9.

Received 16 September 2008 ,Revised 16 January 2009 ,Accepted 23 January 2009.

References 

  1. Kransdorf MJ. Malignant soft-tissue tumors in a large referral population: distribution of diagnoses by age, sex, and location. Am J Roentgenol. 1995;164:129–134
  2. Orvieto E, Furlanetto A, Laurino L, Del Tos AP. Myxoid and round cell liposarcoma: a spectrum of myxoid adipocytic neoplasia. Semin Diagn Pathol. 2001;18:267–273
  3. ten Heuvel SE, Hoekstra HJ, van Ginkel RJ, Bastiaannet E, Suurmeijer AJ. Clinicopathologic prognostic factors in myxoid liposarcoma: a retrospective study of 49 patients with long-term follow-up. Ann Surg Oncol. 2007;14:222–229
  4. Huang HY, Antonescu CR. Molecular variability of TLS-CHOP structure shows no significant impact on the level of adipogenesis: a comparative ultrastructural and RT-PCR analysis of 14 cases of myxoid/round cell liposarcomas. Ultrastruct Pathol. 2003;27:217–226
  5. Antonescu CR. The role of genetic testing in soft tissue sarcoma. Histopathology. 2006;48:13–21
  6. Oikawa K, Ishida T, Imamura T, et al. Generation of the novel monoclonal antibody against TLS/EWS-CHOP chimeric oncoproteins that is applicable to one of the most sensitive assays for myxoid and round cell liposarcomas. Am J Surg Pathol. 2006;30:351–356
  7. Antonescu CR, Tschernyavsky SJ, Decuseara R, et al. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res. 2001;7:3977–3987
  8. Riggi N, Cironi L, Provero P, et al. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res. 2006;66:7016–7023
  9. Kuroda M, Ishida T, Takanashi M, Satoh M, Machinami R, Watanabe T. Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein. Am J Pathol. 1997;151:735–744
  10. Perez-Losada J, Sanchez-Martin M, Rodriguez-Garcia MA, et al. Liposarcoma initiated by FUS/TLS-CHOP: the FUS/TLS domain plays a critical role in the pathogenesis of liposarcoma. Oncogene. 2000;19:6015–6022
  11. Adelmant G, Gilbert JD, Freytag SO. Human translocation liposarcoma-CCAAT/enhancer binding protein (C/EBP) homologous protein (TLS-CHOP) oncoprotein prevents adipocyte differentiation by directly interfering with C/EBPbeta function. J Biol Chem. 1998;273:15574–15581
  12. Barone MV, Crozat A, Tabaee A, Philipson L, Ron D. CHOP (GADD153) and its oncogenic variant, TLS-CHOP, have opposing effects on the induction of G1/S arrest. Genes Dev. 1994;8:453–464
  13. Nielsen TO, West RB, Linn SC, et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet. 2002;359:1301–1307
  14. Matushansky I, Hernando E, Socci ND, et al. A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Am J Pathol. 2008;172:1069–1080
  15. Baird K, Davis S, Antonescu CR, et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res. 2005;65:9226–9235
  16. Henderson SR, Guiliano D, Presneau N, et al. A molecular map of mesenchymal tumors. Genome Biol. 2005;6:R76
  17. Nakayama R, Nemoto T, Takahashi H, et al. Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol. 2007;20:749–759
  18. Coindre JM. Grading of soft tissue sarcomas: review and update. Arch Pathol Lab Med. 2006;130:1448–1453
  19. Nielsen TO, Hsu FD, O'Connell JX, et al. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol. 2003;163:1449–1456
  20. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;65–70
  21. Fajas L, Fruchart JC, Auwerx J. Transcriptional control of adipogenesis. Curr Opin Cell Biol. 1998;10:165–173
  22. Kim KA, Kim JH, Wang Y, Sul HS. Pref-1 (preadipocyte factor 1) activates the MEK/extracellular signal-regulated kinase pathway to inhibit adipocyte differentiation. Mol Cell Biol. 2007;27:2294–2308
  23. Wiper-Bergeron N, Salem HA, Tomlinson JJ, Wu D, Hache RJ. Glucocorticoid-stimulated preadipocyte differentiation is mediated through acetylation of C/EBPbeta by GCN5. Proc Natl Acad Sci USA. 2007;104:2703–2708
  24. Quinkler M, Stewart PM. Hypertension and the cortisol-cortisone shuttle. J Clin Endocrinol Metab. 2003;88:2384–2392
  25. Mazid MA, Chowdhury AA, Nagao K, et al. Endogenous 15-deoxy-Delta(12,14)-prostaglandin J(2) synthesized by adipocytes during maturation phase contributes to upregulation of fat storage. FEBS Lett. 2006;580:6885–6890
  26. Shao D, Lazar MA. Peroxisome proliferator activated receptor gamma, CCAAT/enhancer-binding protein alpha, and cell cycle status regulate the commitment to adipocyte differentiation. J Biol Chem. 1997;272:21473–21478
  27. Grimaldi PA. Peroxisome proliferator-activated receptors as sensors of fatty acids and derivatives. Cell Mol Life Sci. 2007;64:2459–2464
  28. Wang Y, Kim KA, Kim JH, Sul HS. Pref-1, a preadipocyte secreted factor that inhibits adipogenesis. J Nutr. 2006;136:2953–2956
  29. Hauner H, Entenmann G, Wabitsch M, et al. Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J Clin Invest. 1989;84:1663–1670
  30. Gregoire F, Genart C, Hauser N, Remacle C. Glucocorticoids induce a drastic inhibition of proliferation and stimulate differentiation of adult rat fat cell precursors. Exp Cell Res. 1991;196:270–278
  31. Draper N, Stewart PM. 11beta-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol. 2005;186:251–271
  32. Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 2005;16:441–467
  33. Tao Y, Pinzi V, Bourhis J, Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer. Nat Clin Pract Oncol. 2007;4:591–602
  34. Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist. 2007;12:1007–1018
  35. Plaza-Menacho I, Mologni L, Sala E, et al. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem. 2007;282:29230–29240

☆ This work was supported by a grant from the Canadian Institutes for Health Research (Ottawa, ON, Canada). TON is a Senior Scholar of the Michael Smith Foundation for Health Research (Vancouver, BC, Canada). The Genetic Pathology Evaluation Centre (Vancouver, BC, Canada) is supported by an unrestricted educational grant from Sanofi-Aventis (Laval, PQ, Canada).

PII: S0046-8177(09)00032-X

doi: 10.1016/j.humpath.2009.01.011

Human Pathology
Volume 40, Issue 9 , Pages 1244-1251 , September 2009

Article Tools

* Image Usage & Resolution